Document is current
Any future updates will be listed below
-
Authors
Svedbo Engström, Maria https://orcid.org/0000-0002-8267-592X
Leksell, Janeth
Johansson, Unn-Britt
Borg, Sixten
Palaszewski, Bo
Franzén, Stefan
Gudbjörnsdottir, Soffia
Eeg-Olofsson, Katarina
-
Funding
Funding for this research was provided by:
Dalarna University, Falun, Sweden (.)
Uppsala University, Uppsala, Sweden (.)
Sahlgrenska University Hospital, Gothenburg, Sweden (.)
Swedish Diabetes Foundation (.)
Sophiahemmet Foundation, Stockholm, Sweden (.)
AstraZeneca (.)
MSD (.)
Novo Nordisk (.)
Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (ALFGBG-698991)
Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (ALFGBG-725311)
- License Information
-
More Information
Article History
Received: 10 May 2019
Accepted: 7 August 2019
First Online: 14 August 2019
Ethics approval and consent to participate
: The study conforms to the Declaration of Helsinki and was approved by the Regional Ethical Review Board in Gothenburg, Sweden (No. 029–15, T600–15). Participants gave their informed consent.
: Not applicable.
: SG has received personal fees (lecture fees and research grants) from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk, and Sanofi. KEO has received personal lecture fees from Eli Lilly and Abbott. The other authors declare that they have no competing interests.
